Drug Safety in Labeling for Pediatric Drug Development and Dose Selection in Submissions to the US Food and Drug Administration. (29th June 2021)

• Record Type: Journal Article
• Authors: Kim, Clara; Park, Kyunghun; McMahon, Ann W.; Green, Francis G.; Green, Dionna J.; Burckart, Gilbert J.
• Other Names: Burckart Gilbert J. guestEditor.; van den Anker John N. guestEditor.
• Is Part Of: Journal of clinical pharmacology. Volume 61(2021)Supplement 1
• Page Start: S133
• Page End: S140
• Publication Date: 2021-06-29
• Subjects: drug development -- FDA -- labels -- pediatrics (PED) -- safety; Pharmacology -- Periodicals; Pharmacology -- Periodicals; Pharmacology, Clinical -- Periodicals; 615.1
• DOI: 10.1002/jcph.1864
• Languages: English
• ISSNs: 0091-2700

Abstract

Abstract: Pediatric safety evaluations are an essential part of a pediatric drug development program. Communication of the results of these safety evaluations is primarily accomplished by labeling of the drug either during the initial pediatric drug development program, or during the postmarketing period after drug approval for pediatric patients. During drug development, the dose–adverse drug event (ADE) relationship is an important part of the evaluation, but a consideration for pediatric ADEs that are unrelated to drug dosage must be maintained. Examples of dose‐related and non–dose‐related ADEs are presented. The failure to label a product for pediatric use has been safety related for a number of development programs. The US Food and Drug Administration's Pediatric Advisory Committee is a primary source of the pediatric postmarketing safety review and has been associated with a number of labeling changes through its ongoing review process. Pediatric drug safety remains a critical part of the assessment of dose‐effect relationship in the pediatric patient population during the drug development and postmarketing surveillance process.